News >

Emerging Immunotherapy Target in Spotlight at Wistar

Anita T. Shaffer @Shaffer1
Published: Wednesday, Jun 22, 2016

Dmitry I. Gabrilovich, MD, PhD

Dmitry I. Gabrilovich, MD, PhD

Amid growing evidence of their importance in the immune system, myeloid-derived suppressor cells (MDSCs) are gaining traction as a target for anticancer therapies, according to Dmitry I. Gabrilovich, MD, PhD, a leading expert in the field.

Combination Studies Underway

One budding area of research consists of combining agents that target MDSC activity with checkpoint immunotherapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication